67% of U.S. SynCardia Certified Centers Make Becker's 100 Great American Hospitals List Becker's Hospital Review Focuses on Cutting-Edge Healthcare Information for Hospital and Healthcare Leaders
TUCSON, Ariz., April 8, 2014 /PRNewswire/ -- More than two-thirds, 35, of SynCardia's 52 Certified Centers in the United States are on the "100 Great Hospitals in America" list published by Becker's Hospital Review.
"When more than a third of America's top 100 hospitals have the SynCardia temporary Total Artificial Heart it clearly demonstrates that our device is rapidly becoming the standard of care for end-stage biventricular heart failure," says Michael P. Garippa, SynCardia Systems, Inc. CEO and President.
SynCardia Certified Centers use the SynCardia Total Artificial Heart to save patients dying from end-stage biventricular (both sides) heart failure and bridge them to a donor heart transplant. It is the world's first and only FDA, Health Canada and CE approved Total Artificial Heart.
Like a heart transplant, the SynCardia Total Artificial Heart replaces the two failing heart ventricles and four valves. It is the only approved device in the world that eliminates the source and symptoms of end-stage biventricular heart failure.
Becker's Hospital Review cited the cardiology and cardiac surgery services at many of these SynCardia hospitals as reasons they were included in the list. The editorial staff of the publication for high-level hospital leaders compiled the list from research efforts, nominations and evaluations of hospital ranking sources such as U.S. News & World Report, Truven Health Analytics and Healthgrades.
There are 97 SynCardia Certified Centers worldwide with an additional 39 hospitals in the process of completing the four-phase certification program. Nearly 1,300 SynCardia Heart implants have been performed worldwide, including 400 since 2011.
>> Read what Becker's Hospital Review says about its "100 Great Hospitals in America."
CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,260 implants of the Total Artificial Heart, accounting for more than 350 patient years of life on the device.
Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at 97 SynCardia Certified Centers worldwide with 39 others in the process of certification.
The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.
SOURCE SynCardia Systems, Inc.